Kevin Holden, PhD is Head of Synthetic Biology at Synthego in Redwood City, California. He is part of a team responsible for integrating synthetic biology workflows, such as CRISPR genome engineering, into novel automation platforms for cell engineering. In addition, he oversees collaborations with key opinion leaders in the CRISPR research community and supports commercial activities by coordinating technical field application support for Synthego’s portfolio of genome engineering solutions. Kevin frequently represents Synthego at academic and industry conferences, presenting the company’s latest research and development efforts.
Kevin has over 12 years of biotechnology experience that includes collaborative research and development in synthetic biology and genome engineering. He earned his PhD in Microbiology with a Designated Emphasis in Biotechnology from The University of California, Davis. He is originally from the United Kingdom and immigrated to the United States in his youth.